Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10‐year follow‐up

Abstract

OBJECTIVETo evaluate the efficacy of primary hormone therapy for localized or locally advanced prostate cancer, by analysing the 10‐year survival rates for men with localized or locally advanced prostate cancer treated with primary hormone therapy or prostatectomy.PATIENTS AND METHODSBetween February 1993 and March 1995, men with T1b, T1c or T2‐3 N0M0 prostate cancer were enrolled. In all, 176 men who had a prostatectomy were assigned to Study 1 and were given adjuvant luteinizing hormone‐releasing hormone (LHRH) agonist; 151 men who did not have a prostatectomy were assigned to Study 2 and had LHRH agonist monotherapy or combined androgen blockade. They were followed until death, loss to follow‐up, or until the end of the observation period (31 March 2004). We analysed all cases in each study as a single population, and compared Study 1 with Study 2.RESULTSThe mean patient ages were 67.2 years in Study 1 and 75.7 years in Study 2. During a median of 10.4 years of follow‐up, 20 men in Study 1 and 17 in Study 2 died from prostate cancer, and 21 men in Study 1 and 50 in Study 2 died from other causes. In Study 1, the 10‐year overall survival rate was 73% and the 10‐year cause‐specific survival rate was 86%, vs 41% and 78% in Study 2. Overall survival curves were similar to expected survival curves in both studies. There was no significant difference between studies in cause‐specific survival.CONCLUSIONSThe progression of prostate cancer was retarded by primary hormone therapy in men with localized or locally advanced prostate cancer. With primary hormone therapy or prostatectomy, the men had a life‐expectancy similar to that of the normal population.